Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
NEW YORK, March 04, 2016 -- Remedy Pharmaceuticals, a privately-held, pharmaceutical company focused on bringing life saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced the successful completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), which took place on March 2, 2016.
“Our End-of-Phase 2 meeting was a decisive milestone for the Company as we advance the clinical development of CIRARA™,” states Sven Jacobson, Chief Executive Officer of Remedy Pharmaceuticals. “We are pleased with the FDA’s guidance on our Phase 3 trial design in patients with large hemispheric stroke and we look forward to initiating the study as quickly as possible.”
“There is a major unmet medical need to treat CNS-related edema,” said David Geliebter, Executive Chairman of Remedy Pharmaceuticals. “The encouraging data from our Phase 2 studies suggest CIRARA has the potential to reduce mortality and improve functional outcomes for patients with large hemispheric strokes. We’re now one step closer to achieving that goal.”
ABOUT CIRARA
CIRARA is a patented, high affinity inhibitor of Sur1-Trpm4 channels, discovered by University of Maryland neurosurgeon Dr. J. Marc Simard. CIRARA is suitable for intravenous delivery at the bedside or even in an ambulance. CIRARA uses our proprietary, patented MPD™ measured phase dosing technology. CIRARA is an investigational drug and is not approved by FDA.
ABOUT REMEDY PHARMACEUTICALS
Remedy Pharmaceuticals, Inc. is a privately-held, clinical stage pharmaceutical company focused on developing and bringing lifesaving treatment to millions of people affected by acute central nervous system (CNS) edema – including stroke, traumatic brain injury, spinal cord injury, as well as other ischemic injuries and neurological disorders.
Contact: Remedy Pharmaceuticals Sven Jacobson 212-586-2226 x 225 [email protected] Investors Lee Roth / Tram Bui, The Ruth Group 646-536-7012 / 646-536-7035 [email protected] / [email protected] Media Kirsten Thomas, The Ruth Group 508-280-6592 [email protected]
